Canada \u00b7 Comparison
Mounjaro vs Ozempic in Canada: tirzepatide vs semaglutide.
Canadians compare Mounjaro and Ozempic when choosing a GLP-1-class option with a prescriber. This page stays factual: molecules, authorization, coverage pointers and live user-report stats — no dosing or sales.
Molecule and brands
- Ozempic — semaglutide for type 2 diabetes (details). Weight-management semaglutide is Wegovy.
- Mounjaro — tirzepatide (details). Weight-management tirzepatide is Zepbound.
- Class overview: GLP-1 medications in Canada.
Coverage pointers
Unauthorized look-alikes
Compounded or “research” semaglutide/tirzepatide are not authorized drugs — April 2026 advisory. See compounded GLP-1 in Canada.
What semaglutide users report
- 37 published anonymous semaglutide confessions; 5 mention at least one side effect.
- 12 mention Ozempic, Wegovy or Rybelsus by name.
- Among confessions that state a weight change in pounds, the median reported is 50 lb. Self-reported, unverified.
Most-mentioned side effects (share of semaglutide confessions):
- Burping: 5.4% (2)
- Nausea: 5.4% (2)
- Vomiting: 5.4% (2)
- Anxiety or panic: 2.7% (1)
- Constipation: 2.7% (1)
Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: semaglutide side-effects report.
What tirzepatide users report
- 93 published anonymous tirzepatide confessions; 27 mention at least one side effect.
- 10 mention Mounjaro or Zepbound by name.
- Among confessions that state a weight change in pounds, the median reported is 50 lb. Self-reported, unverified.
Most-mentioned side effects (share of tirzepatide confessions):
- Heart rate or palpitations: 11.8% (11)
- Anxiety or panic: 5.4% (5)
- Burping: 4.3% (4)
- Insomnia or poor sleep: 3.2% (3)
- Libido: 3.2% (3)
Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: tirzepatide side-effects report.
What head-to-head data shows
| Trial | Finding |
|---|---|
| SURPASS-2 (type 2 diabetes, 40 weeks) | Tirzepatide lowered HbA1c and weight more than semaglutide 1 mg |
| SURMOUNT-5 (obesity, 72 weeks) | Tirzepatide: about 20% weight loss vs about 14% with semaglutide |
| Side effects | Similar GI profile: nausea, diarrhea, vomiting, constipation |
Detail: Mounjaro side effects, Ozempic side effects.
Last reviewed October 15, 2026against Health Canada's Drug Product Database and NEJM trial publications.
Related
Frequently asked questions
- Is Mounjaro stronger than Ozempic?
- In head-to-head trials tirzepatide lowered blood sugar and weight more than semaglutide, but side effects and individual response vary.
- Is Mounjaro the same as Ozempic?
- No. Ozempic is semaglutide (GLP-1). Mounjaro is tirzepatide (GIP/GLP-1 dual agonist). Both are prescription drugs authorized by Health Canada.
- Which is covered in Canada?
- Coverage is plan-specific. Ozempic has clearer diabetes formulary pathways in some provinces; Mounjaro/Zepbound criteria differ. Check our coverage pages and your pharmacist.
- Is Zepbound part of this comparison?
- Zepbound is tirzepatide for weight management; Mounjaro is the diabetes-facing brand. See our Zepbound and Mounjaro Canada pages.
- Does this page recommend a product, clinic or dose?
- No. We don't list clinics, sellers, prices or doses, and nothing here is medical advice. Talk to a licensed Canadian prescriber or pharmacist.
Sources
General information only — not medical, legal or regulatory advice. Peptide Confessions does not sell, source or recommend any product or vendor, and nothing here is dosing guidance. Speak with a licensed Canadian healthcare professional or pharmacist about any medication. Editorial process →